Merck-AstraZeneca breast cancer drug Lynparza improves long-term survival, clinical trial shows


Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBCRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.

Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBCRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.

Jaime Grajales Benjumea—Getty Images


Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *